HM vs Fibreglass Casts in Treating Pediatric Supracondylar Humeral Fractures

Sponsor
KK Women's and Children's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05430074
Collaborator
(none)
100
1
2
4
24.9

Study Details

Study Description

Brief Summary

Supracondylar humeral fractures are the most common elbow fractures in children and cast immobilization continues to remain as the recommended treatment for modified Gartland's classification Type I and Type IIa injuries. Apart from plaster of Paris and fibreglass casts, the use of waterproof, tubular hybrid mesh (HM) casts have been gaining traction for cast immobilization. Although the use of HM cast has been reported to have similar clinical outcomes and overall patient satisfaction scores to the fibreglass cast, the results of the recent studies are only limited and generalizable only to paediatric distal radius fractures.

As the application method of HM and fibreglass casts are fundamentally different, it has not been reported if the difference in application duration between the cast materials is significant and its potential implications in outpatient clinic operation.

Hence, through a randomized controlled trial, this study primarily aims to investigate if the clinical outcomes, patient satisfaction and duration of cast application with the HM casts would be comparable with fibreglass casts in children with supracondylar humeral fractures.

Through this study, the investigators hope to evaluate the advantages and disadvantages of the respective casting material which may better aid physicians in deciding a more appropriate cast material for treating paediatric supracondylar humeral fractures with cast immobilization and the implications of casting duration on clinic operations.

Condition or Disease Intervention/Treatment Phase
  • Device: HM Cast
  • Device: Fibreglass Cast
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treatment of Paediatric Supracondylar Humeral Fracture With Cast Immobilization: A Randomized Controlled Trial - Hybrid Mesh Versus Fibreglass
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: HM Cast

Device: HM Cast
Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.

Other: Fibreglass Cast

Device: Fibreglass Cast
Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.

Outcome Measures

Primary Outcome Measures

  1. Clinical Outcome - Loss of Reduction [4 weeks post-casting]

    Based on the radiographs taken 4 weeks after casting, the Baumann's angle will used to assess for any loss of reduction.

  2. Comfort and Overall Satisfaction [4 weeks post-casting]

    Through a questionnaire, the patients and their parents will be asked to rate the patients' experience on adaptability, weight of the cast, itch, heat, sweatiness, smell, comfort and overall satisfaction. For each question, on the scales of 1 to 5, the rating of 1 would designate as the least desirable option and the rating of 5 being the most desirable option.

  3. Presence of Skin Rash [4 weeks post-casting]

    The presence of skin rash will be assessed by the study team member upon cast removal.

Secondary Outcome Measures

  1. Duration of Cast Application [During Procedure (Cast Application - First Visit)]

    The duration of each cast application with the respective cast materials will be recorded and analysed.

Other Outcome Measures

  1. Water Contact (For HM casts only) [4 weeks post-casting]

    Through a questionnaire, patients with HM casts will be asked if they had wetted their casts during showers/baths and if they had participated in any water activities (such as swimming or visits to the waterparks).

  2. Duration and Intensity of Pain [4 weeks post-casting]

    Patients will be assessed based on the duration and intensity of pain, and the duration of painkillers used. The intensity of the pain will be assessed via the Faces Pain Scale - Revised, which is a validated self-reporting measure for children to score their pain on rating from 0 to 10, with 0 being "No pain" and 10 being "Very much pain".

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Years to 10 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • First Presentation of Supracondylar humeral fracture (Type I and IIa modified Gartland's classification)
Exclusion Criteria:
  • Prior treatment of supracondylar humeral fracture

  • Previous elbow injuries

  • Open fractures

  • Polytrauma

  • Neurovascular injuries

Contacts and Locations

Locations

Site City State Country Postal Code
1 KK Women's and Children Hospital Singapore Singapore 229899

Sponsors and Collaborators

  • KK Women's and Children's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kenneth Wong Pak Leung, Consultant, KK Women's and Children's Hospital
ClinicalTrials.gov Identifier:
NCT05430074
Other Study ID Numbers:
  • No Protocol ID Assigned Yet
First Posted:
Jun 24, 2022
Last Update Posted:
Jun 24, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kenneth Wong Pak Leung, Consultant, KK Women's and Children's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 24, 2022